Next Article in Journal
Activity of N-Chlorotaurine against Periodontal Pathogens
Previous Article in Journal
The Role of Adipocytes Recruited as Part of Tumor Microenvironment in Promoting Colorectal Cancer Metastases
Previous Article in Special Issue
Methionine Sulfoxide Speciation in Mouse Hippocampus Revealed by Global Proteomics Exhibits Age- and Alzheimer’s Disease-Dependent Changes Targeted to Mitochondrial and Glycolytic Pathways
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
IJMS
Volume 25
Issue 15
10.3390/ijms25158354
ijms-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
This is an early access version, the complete PDF, HTML, and XML versions will be available soon.
Communication

Serum Beta-Secretase 1 Activity Is a Potential Marker for the Differential Diagnosis between Alzheimer’s Disease and Frontotemporal Dementia: A Pilot Study

by
Claudia Saraceno
1,†,
Carlo Cervellati
2,†,
Alessandro Trentini
3,
Daniela Crescenti
1,
Antonio Longobardi
1,
Andrea Geviti
4,
Natale Salvatore Bonfiglio
4,
Sonia Bellini
1,
Roland Nicsanu
1,
Silvia Fostinelli
5,
Gianmarco Mola
2,
Raffaella Riccetti
3,
Davide Vito Moretti
6,
Orazio Zanetti
7,
Giuliano Binetti
5,
Giovanni Zuliani
2 and
Roberta Ghidoni
1,*
1
Molecular Markers Laboratory, IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli, 25125 Brescia, Italy
2
Department of Translational Medicine and for Romagna, University of Ferrara, 44121 Ferrara, Italy
3
Department of Environmental and Prevention Sciences, University of Ferrara, 44121 Ferrara, Italy
4
Service of Statistics, IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli, 25125 Brescia, Italy
5
MAC–Memory Clinic and Molecular Markers Laboratory, IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli, 25125 Brescia, Italy
6
Alzheimer’s Rehabilitation Operative Unit, IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli, 25125 Brescia, Italy
7
Alzheimer’s Research Unit, IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli, 25125 Brescia, Italy
*
Author to whom correspondence should be addressed.
†
These authors contributed equally to this work.
Int. J. Mol. Sci. 2024, 25(15), 8354; https://doi.org/10.3390/ijms25158354 (registering DOI)
Submission received: 5 July 2024 / Revised: 23 July 2024 / Accepted: 28 July 2024 / Published: 30 July 2024
(This article belongs to the Special Issue Molecular Mechanism in the Pathogenesis of Alzheimer’s Disease and Related Neurodegenerative Diseases)
Review Reports Versions Notes

Abstract

Alzheimer’s disease (AD) and frontotemporal dementia (FTD) are the two major neurodegenerative diseases causing dementia. Due to similar clinical phenotypes, differential diagnosis is challenging without specific biomarkers. Beta-site Amyloid Precursor Protein cleaving enzyme 1 (BACE1) is a β-secretase pivotal in AD pathogenesis. In AD and mild cognitive impairment subjects, BACE1 activity is increased in brain/cerebrospinal fluid, and plasma levels appear to reflect those in the brain. In this study, we aim to evaluate serum BACE1 activity in FTD, since, to date, there is no evidence about its role. The serum of 30 FTD patients and 30 controls was analyzed to evaluate (i) BACE1 activity, using a fluorescent assay, and (ii) Glial Fibrillary Acid Protein (GFAP) and Neurofilament Light chain (NfL) levels, using a Simoa kit. As expected, a significant increase in GFAP and NfL levels was observed in FTD patients compared to controls. Serum BACE1 activity was not altered in FTD patients. A significant increase in serum BACE1 activity was shown in AD vs. FTD and controls. Our results support the hypothesis that serum BACE1 activity is a potential biomarker for the differential diagnosis between AD and FTD.
Keywords: BACE1; Alzheimer’s disease; frontotemporal dementia; GFAP; NfL; serum; biomarker; differential diagnosis BACE1; Alzheimer’s disease; frontotemporal dementia; GFAP; NfL; serum; biomarker; differential diagnosis

Share and Cite

MDPI and ACS Style

Saraceno, C.; Cervellati, C.; Trentini, A.; Crescenti, D.; Longobardi, A.; Geviti, A.; Bonfiglio, N.S.; Bellini, S.; Nicsanu, R.; Fostinelli, S.; et al. Serum Beta-Secretase 1 Activity Is a Potential Marker for the Differential Diagnosis between Alzheimer’s Disease and Frontotemporal Dementia: A Pilot Study. Int. J. Mol. Sci. 2024, 25, 8354. https://doi.org/10.3390/ijms25158354

AMA Style

Saraceno C, Cervellati C, Trentini A, Crescenti D, Longobardi A, Geviti A, Bonfiglio NS, Bellini S, Nicsanu R, Fostinelli S, et al. Serum Beta-Secretase 1 Activity Is a Potential Marker for the Differential Diagnosis between Alzheimer’s Disease and Frontotemporal Dementia: A Pilot Study. International Journal of Molecular Sciences. 2024; 25(15):8354. https://doi.org/10.3390/ijms25158354

Chicago/Turabian Style

Saraceno, Claudia, Carlo Cervellati, Alessandro Trentini, Daniela Crescenti, Antonio Longobardi, Andrea Geviti, Natale Salvatore Bonfiglio, Sonia Bellini, Roland Nicsanu, Silvia Fostinelli, and et al. 2024. "Serum Beta-Secretase 1 Activity Is a Potential Marker for the Differential Diagnosis between Alzheimer’s Disease and Frontotemporal Dementia: A Pilot Study" International Journal of Molecular Sciences 25, no. 15: 8354. https://doi.org/10.3390/ijms25158354

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Article metric data becomes available approximately 24 hours after publication online.
Back to TopTop